SARS-CoV-2 and probable lung cancer risk

Sajad Khiali ¹ , Afra Rezagholizadeh ¹ , Taher Entezari-Maleki ^1,2 *

Cited by CrossRef: 1

1- Zeitlmayr S, Cami D, Selmani B, Gudermann T, Breit A. A dual role for ERK-1/2 in the regulation of plasmin activity and cell migration in metastatic NSCLC-H1299 cells. Arch Toxicol. 2023;97(12):3113 [Crossref]

2- Petersen E, Chudakova D, Erdyneeva D, Zorigt D, Shabalina E, Karalkin P, Reshetov I. Cancer as a potential sequela of COVID-19 — should we modify 3D cell culture models accordingly?. BioComm. 2023;68(3) [Crossref]

3- Alqaissi E, Alotaibi F, Sher Ramzan M, Algarni A. Novel graph-based machine-learning technique for viral infectious diseases: application to influenza and hepatitis diseases. Annals of Medicine. 2023;55(2) [Crossref]

4- Xian J, Huang H, Huang G, Zhou R, Yang M, Qiu Y, Bi L, Su Z, Xiao F, Shan H, Jin H. A Positron Emission Tomography Tracer Targeting the S2 Subunit of SARS-CoV-2 in Extrapulmonary Infections. Mol Pharmaceutics. 2022;19(11):4264 [Crossref]

Submit Your Paper Instructions for Authors Aims and Scope Editorial Board Editorial Policies Publication Ethics Policies Editorial Board Policy Abstracting and Indexing Archive

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences.
Acceptance rate: 24%
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded, Google Scholar; SJR ; Essential Science Indicators; Publons; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO; Ulrich
Member of COPE
Follower of ICMJE
Permission: Creative Commons